Table 2.
Outcome and ICU-specific therapies both in the full patient population as well as in the matched-pair analysis (sex, age). No significant differences were identified between the SARS-CoV2 Alpha variant group and the SARS-CoV2 wild-type group. MV = mechanical ventilation; NIV = non-invasive ventilation; HFNO = high-flow nasal oxygen.
| Full Patient Population (n = 160) | Matched-Pair Analysis (n = 116) | |||||
|---|---|---|---|---|---|---|
| Alpha (n = 80) | Wild Type (n = 80) | p | Alpha (n = 58) | Wild Type (n = 58) | p | |
| ICU survival | 41/80 (51%) | 35/80 (44%) | 0.429 | 28/58 (48%) | 27/58 (47%) | 1 |
| Hospital survival | 33/75 (44%) | 34/80 (43%) | 0.872 | 22/53 (42%) | 26/58 (45%) | 0.848 |
| 28-day survival | 36/71 (51%) | 36/79 (46%) | 0.624 | 24/51 (47.1%) | 29/58 (50%) | 0.848 |
| Mechanical ventilation | 61/80 (76%) | 52/80 (65%) | 0.165 | 45/58 (78%) | 38/58 (66%) | 0.217 |
| Duration of mechanical ventilation (days) (median, range) |
16 (2–61) | 14 (1–55) | 0.814 | 16 (2–61) | 14.5 (1–55) | 0.694 |
| Duration of mechanical ventilation of ICU survivors (days) (median, range) | 11 (3–61) [n = 23] | 12 (1–55) [n = 18] | 0.814 | 13.5 (3–61) [n = 28] | 13 (1–55) [n = 15] | 0.694 |
| Duration of NIV/HFNO in patients with no MV (days) (median, range) |
6 (2–14) [n= 16] | 5.5 (1–20) [n = 16] | 0.934 | 5 (2–9) [n = 11] | 4 (1–13) [n = 11] | 0.844 |
| ECMO | 6/80 (8%) | 14/79 (18%) | 0.059 | 10/58 (17%) | 6/58 (10%) | 0.420 |
| Renal replacement therapy | 17/77 (22%) | 23/80 (29%) | 0.365 | 13/56 (23%) | 17/58 (29%) | 0.526 |